Organon & Co.

OGNintermediary

Organon is a women's health-focused pharmaceutical company spun off from Merck in 2021, combining contraceptive and fertility products with a growing biosimilars portfolio.

⇄ Compare

Produkte & Umsatz

Umsatzanteil nach Produkt

Umsatzaufschlüsselung ($6.3B)

Statische Daten (Echtzeitfinanzen werden geladen…)

Women's Health (28%)

Biosimilars (18%)

Established Brands (54%)

Segmentzusammensetzung und Hauptkunden

Produktdetails

Nexplanon25%

Long-acting reversible contraceptive implant — #1 in its class

Fertility (Follistim, Ganirelix)15%

Hormone therapies for assisted reproduction

Biosimilars20%

Renflexis, Hadlima, and other biosimilar products

Established Brands40%

Legacy Merck products including Zetia, Nasonex, Cozaar

Lieferkettenbeziehungen

Partner

Merck & Co.

Spun off from Merck in 2021

Auswirkung: Medium — legacy Merck product rights

Wettbewerber

Viatris Inc.

Biosimilar market

Auswirkung: Medium — competing biosimilar portfolios

Wichtige Kunden

Walgreens Boots Alliance

Pharmacy retail distribution

Auswirkung: Low — indirect distribution

Makro- und Marktkontext

제약 / 바이오Sektornachrichten

GLP-1 메가트렌드 + AI 신약개발 + 저평가 바이오 기관 매집

GLP-1 시장 규모 (2030E)

$150B

mRNA 암백신 임상 성공률

+49% 재발 위험 감소

AI 신약개발 단계

임상 2상 진입

PFE/MRNA 52주 변화

-30% ~ -45%

Nächste Katalysatoren

◆LLY Orforglipron(경구용 GLP-1) 3상 결과 (2026.Q2)◆MRNA 암백신 FDA BLA 제출 예정◆REGN EYLEA HD 유럽 허가 결과

Aktuelle Nachrichten

Nachrichten laden...

KI-Analyse

Klicken Sie auf "KI-Analyse abrufen" für eine KI-gestützte Lieferkettenanalyse von Organon & Co..

Unternehmensinformationen

Hauptsitz

Jersey City, New Jersey, USA

Gegründet

2021

Mitarbeiter

10,000+

Website

organon.com

Sektorübersicht — 제약 / 바이오

Sektornachrichten